Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. - Wikidata - awgldk - TriplyDB

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

http://www.wikidata.org/entity/Q35603195

about

Neuroimaging of Parkinson's disease: Expanding views.Parkinson Disease and Dementia.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.Lewy body dementias.α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP.Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease Neural correlates of attention-executive dysfunction in lewy body dementia and Alzheimer's disease Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.Cognitive decline in Parkinson disease.The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction.Cognitive decline in Parkinson's disease: the complex picture.Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.Update on Molecular Imaging in Parkinson's Disease.Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia.Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease.EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study.Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Imaging Alzheimer's disease pathophysiology with PET.Serotonin, beta-amyloid, and cognition in Parkinson disease.Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?Multi-modality molecular imaging characteristics of dementia with Lewy bodies.Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease Can neuroimaging predict dementia in Parkinson's disease?The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients

P2860

Q28387732-8D068DA9-D16D-4F4B-9D37-F975430EA8F4 Q30248574-E1933FDA-DE84-4514-94DF-C0D023E34654 Q31097119-F04B46FC-1DA4-4C14-AFC0-31892C476D55 Q33727909-9453C110-D4F2-450B-AF34-242B8B757820 Q33869820-A0F50ED6-F7B5-4C29-A722-8AE57AFEFC0F Q34502646-68905126-EC64-458C-BF02-5C13A14278AB Q36277049-457545BC-7C7B-4057-B008-6452879B6A1A Q36494215-AD9705AD-CC60-49AE-BC4D-78A887A4EDE5 Q36667583-2A985C96-1848-4383-B3CF-6EF8A18B3BCE Q36813196-167CC07D-B21F-4F45-AB7C-1A37B0C0C200 Q37633577-6DDAE6D7-F621-4FA1-8CD2-BE8405A33FB5 Q38751099-419F7AC7-02AC-499B-8037-9CDC8A388B39 Q38809233-56E5FFC2-4C7D-4C6B-B6C9-D009CADC7FF1 Q39446566-2156CB29-5907-4C50-8E62-7E15F83C2B63 Q39691980-5BEA4412-A291-4062-916E-40C152B752DD Q41589030-9BB283EF-E569-4DA2-BC97-B3E2574775DA Q41635671-119F9A04-A47D-425D-84D5-B9B08E425BDD Q46255370-8C8D2DE3-48A6-4261-9198-09F4275F642D Q47250613-DDD65F7B-5A9A-46F1-9743-761059E77B06 Q48267581-448B2DC2-DC0B-4338-8D3F-83286C97CC7D Q48348223-C191E790-E91A-4F1D-808E-CCB39B7EEC08 Q48469027-15E5E044-7FB6-4691-AAC6-D26006AC3170 Q48550610-29F0E0FC-65BB-4532-A8EA-ED2314B8660C Q48687926-D40AE6D9-3B90-425C-B878-62B0B963764A Q49295547-5E32D8E1-A309-4DD3-9DE2-55CE157973A6 Q49987358-DFA82FB5-A05E-46DC-A547-BB9C15E8430A Q50044294-FA6BAF92-97D5-4BA2-B9F2-94461DFB3BB2 Q52582953-07FC1009-9907-437F-8EC5-9489BBA7F2DB Q54982491-7542EF5B-BAF0-4E9F-A886-067250565AAA Q55445448-189FFEBB-A79B-4FA7-BCD4-F14B924F79D8 Q57800439-817E5485-B6E4-422F-BC5E-0CD42D2FA1C9 Q58696822-8F613F28-F26B-43C0-B969-C21C35709763 Q58720353-76F27A83-43BE-4E7F-B6E9-95DE26A5D825

P2860

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

http://www.wikidata.org/entity/Q35603195

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@ast

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@en

type

label

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@ast

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@en

prefLabel

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@ast

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@en

P1433

Q35603195-D094FE6C-AC8B-477E-8E0B-A0219E92E496

P1476

Q35603195-F086F502-6505-4A77-93F7-36D74074251C

P2093

Q35603195-0BC33FA7-6D05-4581-9E37-B0A5CCC31823

Q35603195-10C5D843-015F-4A52-8F3B-67FAA35054C8

Q35603195-2104314E-0A0A-46DC-85F5-05731DC7FB4F

Q35603195-8DA61E9E-8A8C-47D3-9CEC-F6045F4BE58E

Q35603195-AAABAEFD-C54D-4F7C-BB89-7A1D6DE4C72C

Q35603195-F3BD73D3-8C9F-4523-81B0-C0B599B0C430

P2860

Q35603195-05DE74A5-C19D-433D-84BB-D61AAB6BB249

Q35603195-0AD31BF2-760C-4FDB-B568-3881D31C3E59

Q35603195-0F2FE5E2-A571-4AF4-A0FF-F77BAD190E83

Q35603195-119BA10C-8D34-4D1D-9F42-E3C8929691A0

Q35603195-11F89194-E27B-4AF0-8C3E-EE04F26F837A

Q35603195-168FE690-C7E9-4A1D-AA13-203EEA6C4FF7

Q35603195-1ED7FCE8-2D68-435B-9B89-047D1548C1C1

Q35603195-279ABF49-210B-42C4-9749-1857103BC568

Q35603195-2AD85039-8785-4918-8CDC-E6D089F9D076

Q35603195-3CE9026D-EEF7-45B9-A8CE-FF5A23F60623

P304

Q35603195-EEFCECAF-26CF-440F-8B41-29CBEC54BFDA

P31

Q35603195-E3C867FD-6512-4B86-848A-47C140E400C5

P356

Q35603195-67A1D7FD-1190-4A21-8005-8C879E7A6F14

P407

Q35603195-377D96DB-F5BB-4992-A5E9-8DCAAF32AA9D

P433

Q35603195-167548D1-B8CC-43D0-BC54-B69ECF5FF4E1

P478

Q35603195-7D75257A-877D-44C6-8355-4C2991D7CEF3

P50

Q35603195-0DF88EE4-E721-4E76-8524-E59625C341DE

Q35603195-5B6A3927-75B9-4109-BDA1-A21370CACBFB

P577

Q35603195-E70DEB27-BF36-4D9D-BB65-377458E3686A

P698

Q35603195-31C20A99-3724-4B8D-B7DD-DA3ED1BC7938

P921

Q35603195-BA09C5A3-986D-4342-8802-711ACF5C2697

P932

Q35603195-4D32EAE0-3CCD-4F59-A805-711A6FBA3F55

P356

P1433

Movement Disorders

P1476

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

@en

P2093

Ben A Dwamena

http://www.w3.org/2001/XMLSchema#string

Bradley R Foerster

http://www.w3.org/2001/XMLSchema#string

Kirk A Frey

http://www.w3.org/2001/XMLSchema#string

Martijn Ltm Müller

http://www.w3.org/2001/XMLSchema#string

Myria Petrou

http://www.w3.org/2001/XMLSchema#string

Roger L Albin

http://www.w3.org/2001/XMLSchema#string

P2860

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews

Measuring inconsistency in meta-analyses

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Amyloid imaging of Lewy body-associated disorders

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.

P304

928-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26191

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Mark MacEachern

Nicolaas I Bohnen

P577

2015-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25879534

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4478091

http://www.w3.org/2001/XMLSchema#string